.png){kind=icon}
With over 80 unique hematological malignancy cell lines, such as the CD19+ Raji-Luc lymphoma model, the MV-411-Luc leukemia model, and the MM.1S-Luc multiple myeloma model, we lead the industry with market-relevant models for your studies. We also have an ever-expanding list of solid tumor models validated in NSG mice to support the field’s drive toward approval of an adoptive cell therapy (ACT) in a solid tumor indication.
Discover an unparalleled breadth of experience in the use of mouse tumor models to evaluate adoptive cell therapies (ACTs). With a broad range of disseminated and subcutaneous tumor models characterized in NSG mice, and a scientific team that knows how to apply them, we can guide selection of the right tumor model for your CAR T cell or other ACT study.
